

NICE TAs 2023			
	TA Subject	Is the Technology Appraisal relevant to Locala?	If yes, does Locala comply with the NICE Technology Appraisal?
TA892	Mosunetuzumab for treating relapsed or refractory follicular lymphoma	No	
TA891	Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia	No	
TA890	Difelikefalin for treating pruritus in people having haemodialysis	No	
TA889	Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal)	No	
TA888	Risankizumab for previously treated moderately to severely active Crohn's disease	No	
TA887	Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer	No	
TA886	Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy	No	
TA885	Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer	No	
TA884	Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal)	No	
TA883	Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma	No	
TA882	Voclosporin with mycophenolate mofetil for treating lupus nephritis	No	

TA881	Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments	No	
TA880	Tezepelumab for treating severe asthma	No	
TA879	Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated	No	
TA878	Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19	No	
TA877	Finerenone for treating chronic kidney disease in type 2 diabetes	No	
TA876	Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer	No	
TA875	Semaglutide for managing overweight and obesity	No	
TA874	Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma	No	
TA873	Cannabidiol for treating seizures caused by tuberous sclerosis complex	No	
TA872	Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies	No	
TA871	Eptinezumab for preventing migraine	No	
TA870	Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma	No	

TA869	Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal)	No	
TA868	Vutrisiran for treating hereditary transthyretin-related amyloidosis	No	
TA867	Mitapivat for treating pyruvate kinase deficiency (terminated appraisal)	No	
TA866	Regorafenib for previously treated metastatic colorectal cancer	No	
TA865	Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma	No	
TA864	Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted	No	
TA863	Somatrogen for treating growth disturbance in children and young people aged 3 years and over	Yes	Yes
TA862	Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments	No	
TA861	Upadacitinib for treating active non-radiographic axial spondyloarthritis	No	
TA860	Maribavir for treating refractory cytomegalovirus infection after transplant	No	
TA859	Angiotensin II for treating vasopressor-resistant hypotension caused by septic or distributive shock (terminated appraisal)	No	
TA858	Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma	No	

TA857	Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma	No	
TA856	Upadacitinib for treating moderately to severely active ulcerative colitis	No	
TA855	Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy	No	
NICE TAs 2022			
TA854	Esketamine nasal spray for treatment-resistant depression	No	
TA853	Avatrombopag for treating primary chronic immune thrombocytopenia	No	
TA852	Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments	No	
TA851	Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer	No	
TA850	Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy	No	
TA849	Cabozantinib for previously treated advanced hepatocellular carcinoma	No	
TA848	Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal)	No	
TA847	Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal)	No	

TA846	Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal)	No	
TA845	Mepolizumab for treating eosinophilic granulomatosis with polyangiitis (terminated appraisal)	No	
TA844	Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal)	No	
TA843	Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal)	No	
TA842	Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies (terminated appraisal)	No	
TA841	Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)	No	
TA840	Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids (terminated appraisal)	No	
TA839	Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids (terminated appraisal)	No	
TA838	Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal)	No	
TA837	Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma	No	
TA836	Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy	No	
TA835	Fostamatinib for treating refractory chronic immune thrombocytopenia	No	

TA834	SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal)	No	
TA833	Zanubrutinib for treating Waldenstrom's macroglobulinaemia	No	
TA832	Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids	No	
TA831	Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer	No	
TA830	Pembrolizumab for adjuvant treatment of renal cell carcinoma	No	
TA829	Upadacitinib for treating active ankylosing spondylitis	No	
TA828	Ozanimod for treating moderately to severely active ulcerative colitis	No	
TA827	Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy	No	
TA826	Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal)	No	
TA825	Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis	No	
TA824	Dexamethasone intravitreal implant for treating diabetic macular oedema	No	
TA823	Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer	No	

TA822	Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal)	No	
TA821	Avalglucosidase alfa for treating Pompe disease	No	
TA820	Brolucizumab for treating diabetic macular oedema	No	
TA819	Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies	No	
TA818	Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma	No	
TA817	Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence	No	
TA816	Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer	No	
TA815	Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs	No	
TA814	Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis	No	
TA813	Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors	No	
TA812	Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer	No	
TA811	Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal)	No	

TA810	Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence	No	
TA809	Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease	No	
TA808	Fenfluramine for treating seizures associated with Dravet syndrome	No	
TA807	Roxadustat for treating symptomatic anaemia in chronic kidney disease	No	
TA806	Belimumab for treating lupus nephritis (terminated appraisal)	No	
TA805	Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides	No	
TA804	Teduglutide for treating short bowel syndrome	No	
TA803	Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs	No	
TA802	Cemiplimab for treating advanced cutaneous squamous cell carcinoma	No	
TA801	Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer	No	
TA800	Faricimab for treating wet age-related macular degeneration	No	
TA799	Faricimab for treating diabetic macular oedema	No	

TA798	Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation	No	
TA797	Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal)	No	
TA796	Venetoclax for treating chronic lymphocytic leukaemia	No	
TA795	Ibrutinib for treating Waldenstrom's macroglobulinaemia	No	
TA794	Diroximel fumarate for treating relapsing–remitting multiple sclerosis	No	
TA793	Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal)	No	
TA792	Filgotinib for treating moderately to severely active ulcerative colitis	No	
TA791	Romosozumab for treating severe osteoporosis	No	
TA790	TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal)	No	
TA789	Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations	No	
TA788	Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy	No	
TA787	Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable	No	

TA786	Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies	No	
TA785	Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal)	No	
TA784	Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer	No	
TA783	Daratumumab monotherapy for treating relapsed and refractory multiple myeloma	No	
TA782	Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal)	No	
TA781	Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer	No	
TA780	Nivolumab with ipilimumab for untreated advanced renal cell carcinoma	No	
TA779	Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency	No	
TA778	Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria	No	
TA777	Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea	No	
TA776	Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea	No	
TA775	Dapagliflozin for treating chronic kidney disease	Yes	Yes

TA774	Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal)	No	
TA773	Empagliflozin for treating chronic heart failure with reduced ejection fraction	Yes	Yes
TA772	Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies	No	
TA771	Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal)	No	
TA770	Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer	No	
TA769	Palforzia for treating peanut allergy in children and young people	No	
TA768	Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs	No	
TA767	Ponesimod for treating relapsing–remitting multiple sclerosis	No	
TA766	Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma	No	
TA765	Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable	No	
TA764	Fremanezumab for preventing migraine	No	
TA763	Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable	No	

TA762	Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal)	No	
TA761	Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection	No	
TA760	Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer	No	
TA759	Fostamatinib for treating refractory chronic immune thrombocytopenia	No	
TA758	Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy	Yes	Yes
TA757	Cabotegravir with rilpivirine for treating HIV-1	No	
NICE TAs 2021			
TA756	Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis	No	
TA755	Risdiplam for treating spinal muscular atrophy	No	
TA754	Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome	No	
TA753	Cenobamate for treating focal onset seizures in epilepsy	No	
TA752	Belimumab for treating active autoantibody-positive systemic lupus erythematosus	No	
TA751	Dupilumab for treating severe asthma with type 2 inflammation	No	

TA750	Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal)	No	
TA749	Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal)	Yes	Yes
TA748	Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders	No	
TA747	Nintedanib for treating progressive fibrosing interstitial lung diseases	No	
TA746	Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer	No	
TA745	NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal)	No	
TA744	Upadacitinib for treating moderate rheumatoid arthritis	No	
TA743	Crizanlizumab for preventing sickle cell crises in sickle cell disease	No	
TA742	Selpercatinib for treating advanced thyroid cancer with RET alterations	No	
TA741	Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer	No	
TA740	Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer	No	
TA739	Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable	No	

TA738	Berotralstat for preventing recurrent attacks of hereditary angioedema	No	
TA737	Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer	No	
TA736	Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy	No	
TA735	Tofacitinib for treating juvenile idiopathic arthritis	No	
TA734	Secukinumab for treating moderate to severe plaque psoriasis in children and young people	No	
TA733	Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia	No	
TA732	Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal)	No	
TA731	Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal)	No	
TA730	Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal)	No	
TA729	Sapropterin for treating hyperphenylalaninaemia in phenylketonuria	No	
TA728	Midostaurin for treating advanced systemic mastocytosis	No	
TA727	Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)	No	

TA726	Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)	No	
TA725	Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy	No	
TA724	Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer	No	
TA723	Bimekizumab for treating moderate to severe plaque psoriasis	No	
TA722	Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement	No	
TA721	Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer	No	
TA720	Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma	No	
TA719	Secukinumab for treating non-radiographic axial spondyloarthritis	No	
TA718	Ixekizumab for treating axial spondyloarthritis	No	
TA717	Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal)	No	
TA716	Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency	No	
TA715	Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed	No	

TA714	Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)	No	
TA713	Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy	No	
TA712	Enzalutamide for treating hormone-sensitive metastatic prostate cancer	No	
TA711	Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs	No	
TA710	Ravulizumab for treating atypical haemolytic uraemic syndrome	No	
TA709	Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency	No	
TA708	Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis	Yes	Yes
TA707	Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer	No	
TA706	Ozanimod for treating relapsing–remitting multiple sclerosis	No	
TA705	Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer	No	
TA704	Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies	No	
TA703	Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal)	No	

TA702	Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal)	No	
TA701	Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal)	No	
TA700	Selinexor with low-dose dexamethasone for treating refractory multiple myeloma (terminated appraisal)	No	
TA699	Ofatumumab for treating relapsing multiple sclerosis	No	
TA698	Ravulizumab for treating paroxysmal nocturnal haemoglobinuria	No	
TA697	Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban	No	
TA696	Tafamidis for treating transthyretin amyloidosis with cardiomyopathy	No	
TA695	Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma	No	
TA694	Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia	No	
TA693	Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer	No	
TA692	Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy	No	
TA691	Avelumab for untreated metastatic Merkel cell carcinoma	No	

TA690	Teduglutide for treating short bowel syndrome (terminated appraisal)	No	
TA689	Acalabrutinib for treating chronic lymphocytic leukaemia	No	
TA688	Selective internal radiation therapies for treating hepatocellular carcinoma	No	
TA687	Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy	No	
TA686	Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)	No	
TA685	Anakinra for treating Still's disease	No	
TA684	Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease	No	
TA683	Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer	No	
TA682	Erenumab for preventing migraine	No	
TA681	Baricitinib for treating moderate to severe atopic dermatitis	No	
TA680	Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma	No	
TA679	Dapagliflozin for treating chronic heart failure with reduced ejection fraction	No	

TA678	Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal)	No	
TA677	Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma	No	
TA676	Filgotinib for treating moderate to severe rheumatoid arthritis	No	
TA675	Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal)	No	
TA674	Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal)	No	
TA673	Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy	No	
TA672	Brolocizumab for treating wet age-related macular degeneration	No	
TA671	Mepolizumab for treating severe eosinophilic asthma	No	
TA670	Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor	No	
TA669	Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies	No	
	NICE TAs 2020		
TA668	Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer	No	
TA667	Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura	No	

TA666	Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma	No	
TA665	Upadacitinib for treating severe rheumatoid arthritis	No	
TA664	Liraglutide for managing overweight and obesity	Yes	Yes
TA663	Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia	No	
TA662	Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal)	No	
TA661	Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma	No	
TA660	Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer	No	
TA659	Galcanezumab for preventing migraine	No	
TA658	Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma	No	
TA657	Carfilzomib for previously treated multiple myeloma	No	
TA656	Siponimod for treating secondary progressive multiple sclerosis	No	
TA655	Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy	No	

TA654	Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer	No	
TA653	Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer	No	
TA652	Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal)	No	
TA651	Naldemedine for treating opioid-induced constipation	Yes	Yes
TA650	Pembrolizumab with axitinib for untreated advanced renal cell carcinoma	No	
TA649	Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma	No	
TA648	Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal)	No	
TA647	Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal)	No	
TA646	Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal)	No	
TA645	Avelumab with axitinib for untreated advanced renal cell carcinoma	No	
TA644	Entrectinib for treating NTRK fusion-positive solid tumours	No	
TA643	Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer	No	

TA642	Gilteritinib for treating relapsed or refractory acute myeloid leukaemia	No	
TA641	Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma	No	
TA640	Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant	No	
TA639	Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer	No	
TA638	Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer	No	
TA637	Ranibizumab for treating diabetic retinopathy (terminated appraisal)	No	
TA636	Eculizumab for treating refractory myasthenia gravis (terminated appraisal)	No	
TA635	Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal)	No	
TA634	Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal)	No	
TA633	Ustekinumab for treating moderately to severely active ulcerative colitis	No	
TA632	Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer	No	
TA631	Fremanezumab for preventing migraine	No	

TA630	Larotrectinib for treating NTRK fusion-positive solid tumours	No	
TA629	Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab	No	
TA628	Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer	No	
TA627	Lenalidomide with rituximab for previously treated follicular lymphoma	No	
TA625	Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal)	No	
TA624	Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis	No	
TA623	Patiromer for treating hyperkalaemia	No	
TA622	Sotagliflozin with insulin for treating type 1 diabetes	Yes	Yes
TA621	Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer	No	
TA620	Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer	No	
TA619	Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer	No	
TA618	Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal)	No	

TA617	Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure	No	
	NICE TAs 2019		
	TA Subject	Is the Technology Appraisal relevant to Locala?	If yes, does Locala comply with the NICE Technology Appraisal?
TA616	Cladribine for treating relapsing–remitting multiple sclerosis	No	
TA615	Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome	No	
TA614	Cannabidiol with clobazam for treating seizures associated with Dravet syndrome	No	
TA613	Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy	No	
TA612	Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab	No	
TA611	Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer	No	
TA610	Pentosan polysulfate sodium for treating bladder pain syndrome	No	
TA609	Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal)	No	
TA608	Ibrutinib with rituximab for treating Waldenstrom’s macroglobulinaemia (terminated appraisal)	No	
TA607	Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease	Yes	Yes

TA606	Lanadelumab for preventing recurrent attacks of hereditary angioedema	No	
TA605	Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea	No	
TA604	Idelalisib for treating refractory follicular lymphoma	No	
TA603	Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal)	No	
TA602	Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)	No	
TA601	Bezlotoxumab for preventing recurrent Clostridium difficile infection (terminated appraisal)	No	
TA600	Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer	No	
TA599	Sodium zirconium cyclosilicate for treating hyperkalaemia	No	
TA598	Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first line platinum	No	
TA597	Dapagliflozin with insulin for treating type 1 diabetes	No	
TA596	Risankizumab for treating moderate to severe plaque psoriasis	No	
TA595	Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer	No	
TA594	Brentuximab vedotin for untreated advanced Hodgkin lymphoma	No	

TA593	Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer	No	
TA592	Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma	No	
TA591	Letermovir for preventing cytomegalovirus disease after a stem cell transplant	No	
TA590	Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis	No	
TA589	Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity	No	
TA588	Nusinersen for treating spinal muscular atrophy	No	
TA587	Lenalidomide plus dexamethasone for previously untreated multiple myeloma	No	
TA586	Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib	No	
TA585	Ocrelizumab for treating primary progressive multiple sclerosis	No	
TA584	Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer	No	
TA583	Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes	Yes	Yes
TA582	Cabozantinib for previously treated advanced hepatocellular carcinoma	No	
TA581	Nivolumab with ipilimumab for untreated advanced renal cell carcinoma	No	

TA580	Enzalutamide for hormone-relapsed non-metastatic prostate cancer	No	
TA579	Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy	No	
TA578	Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum based chemoradiation	No	
TA577	Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma	No	
TA576	Bosutinib for untreated chronic myeloid leukaemia	No	
TA575	Tildrakizumab for treating moderate to severe plaque psoriasis	No	
TA574	Certolizumab pegol for treating moderate to severe plaque psoriasis	No	
TA573	Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma	No	
TA572	Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes	Yes	Yes
TA571	Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib	No	
TA570	Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum based chemotherapy	No	
TA569	Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer	No	
TA568	Abatacept for treating psoriatic arthritis after DMARDs	No	

TA567	Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies	No	
TA566	Cochlear implants for children and adults with severe to profound deafness	No	
TA565	Benralizumab for treating severe eosinophilic asthma	No	
TA564	Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal)	No	
TA563	Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast	No	
TA562	Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma	No	
TA561	Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia	No	
TA560	Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer	No	
TA559	Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies	No	
TA558	Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease	No	
TA557	Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer	No	
TA556	Darvadstrocel for treating complex perianal fistulas in Crohn's disease	No	
TA555	Regorafenib for previously treated advanced hepatocellular carcinoma	No	
	NICE TAs 2018		

	TA Subject	Is the Technology Appraisal relevant to Locala?	If yes, does Locala comply with the NICE Technology Appraisal?
TA554	Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25	No	
TA553	Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence	No	
TA552	Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia	No	
TA551	Lenvatinib for untreated advanced hepatocellular carcinoma	No	
TA550	Vandetanib for treating medullary thyroid cancer	No	
TA549	Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal)	No	
TA548	Decitabine for untreated acute myeloid leukaemia (terminated appraisal)	No	
TA546	Padeliporfin for untreated localised prostate cancer	No	
TA545	Gemtuzumab ozogamicin for untreated acute myeloid leukaemia	No	
TA543	Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs	No	
TA542	Cabozantinib for untreated advanced renal cell carcinoma	No	
TA541	Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia	No	

Ta540	Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma	No	
TA539	Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours	No	
TA538	Dinutuximab beta for treating neuroblastoma	No	
TA537	Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs	No	
TA536	Alectinib for untreated ALK-positive advanced non-small-cell lung cancer	No	
TA535	Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine	No	
TA534	Beta interferons and glatiramer acetate for treating multiple sclerosis	No	
TA533	Ocrelizumab for treating relapsing-remitting multiple sclerosis	No	
TA532	Cenegermin for treating neurotrophic keratitis	No	
TA531	Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell cancer	No	
TA530	Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy	No	
TA529	Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer	No	

TA528	Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer	No	
TA527	Beta interferons and glatiramer acetate for treating multiple sclerosis	No	
TA522	Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable	No	
TA516	Cabozantinib for treating medullary thyroid cancer	No	
TA515	Eribulin for treating locally advanced or metastatic	No	
TA514	Regorafenib for previously treated advanced	No	
TA513	Obinutuzumab for untreated advanced follicular	No	
TA512	Tivozanib for treating advanced renal cell carcinoma	No	
TA511	Brodalumab for treating moderate to severe plaque	No	
TA510	Daratumumab monotherapy for treating relapsed and	No	
TA509	Pertuzumab with trastuzumab and docetaxel for	No	
TA508	Autologous chondrocyte implantation using	No	
TA507	Sofosbuvir–velpatasvir–voxilaprevir for treating	No	
TA506	Lesinurad for treating chronic hyperuricaemia in	No	
TA505	Ixazomib with lenalidomide and dexamethasone for	No	
TA504	Pirfenidone for treating idiopathic pulmonary fibrosis	No	
TA503	Fulvestrant for untreated locally advanced or	No	
TA502	Ibrutinib for treating relapsed or refractory mantle cell	No	
TA501	Intrabeam radiotherapy system for adjuvant treatment	No	
TA500	Ceritinib for untreated ALK-positive non-small-cell lung	No	
TA499	Glecaprevir–pibrentasvir for treating chronic hepatitis	No	
TA498	Lenvatinib with everolimus for previously treated	No	
TA497	Golimumab for treating non-radiographic axial	No	

	TA Subject	Is the recommendation in the TA applicable to organization?	Does Locala comply with the NICE Technology Appraisal?
TA492	<u>Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable</u>	No	
TA491	<u>Ibrutinib for treating Waldenstrom's macroglobulinaemia</u>	No	
TA490	<u>Nivolumab for treat squamous cell carcinoma of the head and neck after platinum-based chemotherapy</u>	No	
TA489	<u>Vismodegib for treating basal cell carcinoma</u>	No	
TA488	<u>Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours</u>	No	
TA487	<u>Venetoclax for treating chronic lymphocytic leukaemia</u>	No	
TA486	<u>Afibercept for treating choroidal neovascularization</u>	No	
TA485	<u>Sarilumab for moderate to severe rheumatoid arthritis</u>	No	
TA484	<u>Nivolumab for previously treated non-squamous non-small-cell lung cancer</u>	No	

TA483	Nivolumab for previously treated squamous non-small-cell lung cancer	No	
TA480	Tocacitinib for moderate to severe rheumatoid arthritis	No	
TA479	Reslizumab for treating sever eosinophilic asthma	No	
TA478	Brentuximab vedotin for treating relapsed or refractory system anaplastic large cell lymphoma	No	
TA477	Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee)	No	
TA462	Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma	No	
TA458	Tratuzumab emtabsine for treating HER2-postive advanced breast cancer after trastuzumab and a taxane	No	
ID579	Psoriatic arthritis - certolizumab pegol and secukinumab (after DMARDs)	No	
ID1017	Apremilast for treating active psoriatic arthritis	No	
TA431	Asthma (eosinophilic, severe) - mepolizumab	No	
TA430	Sofosbuvir–velpatasvir for treating chronic hepatitis C	No	

TA429	Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation	No	
TA428	Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy	No	
TA427	Multiple myeloma (relapsed, refractory) - pomalidomide (after lenalidomide and bortezomib)	No	
NICE TAs 2016			
	TA Subject	Is the recommendation in the TA applicable to organization?	Does Locala comply with the NICE Technology Appraisal?
TA425	Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia	No	
TA424	Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer	No	
TA423	Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens	No	
TA422	Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer	No	
TA421	Everolimus with exemestane for treating advanced breast cancer after endocrine therapy	No	
TA420	Ticagrelor for preventing atherothrombotic events after myocardial infarction	Yes	Yes

TA419	Apremilast for treating moderate to severe plaque psoriasis	No	
TA418	Dapagliflozin in triple therapy for treating type 2 diabetes	Yes	Yes
TA417	Nivolumab for previously treated advanced renal cell carcinoma	No	
TA416	Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer	No	
TA415	Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor	No	
TA414	Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma	No	
TA413	Elbasvir-grazoprevir for treating chronic hepatitis C	No	
TA412	Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases	No	
TA411	Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer	No	
TA410	Talimogene laherparepvec for treating unresectable metastatic melanoma	No	
TA409	Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion	No	
TA408	Pegaspargase for treating acute lymphoblastic leukaemia	No	

TA407	Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors	No	
TA406	Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer	No	
TA405	Trifluridine–tipiracil for previously treated metastatic colorectal cancer	No	
TA401	Bosutinib for previously treated chronic myeloid leukaemia	No	
TA404	Prostate cancer (advanced, hormone dependent) - degarelix depot	No	
TA402	Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin	No	
TA403	Lung cancer (non-small cell, metastatic) - ramucirumab (after platinum chemotherapy)	No	
TA400	Nivolumab in combination with ipilimumab for treating advanced melanoma	No	
TA398	Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation	No	
TA399	Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts	No	
TA394	Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia	No	
TA393	Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia	No	

TA396	Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma	No	
TA397	Belimumab for treating active autoantibody-positive systemic lupus erythematosus	No	
TA392	Adalimumab for treating moderate to severe hidradenitis suppurativa	No	
TA395	Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer	No	
TA390	Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes	Yes	Yes
TA391	Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel	No	
TA389	Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer	No	
TA388	Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction	Yes	Yes
TA387	Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated	No	
TA383	TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis	No	
TA375	Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed	No	

TA382	Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal)	No	
TA377	Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated	No	
TA379	Nintedanib for treating idiopathic pulmonary fibrosis	No	
TA381	Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy	No	
TA380	Panobinostat for treating multiple myeloma after at least 2 previous treatments	No	
TA376	Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases	No	
TA378	Ramucirumab for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy	No	
	NICE TAs 2014-15		
	TA Subject	Is the recommendation in the TA applicable to organization?	Does Locala comply with the NICE Technology Appraisal?
TA373	Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis	No	

TA372	Apremilast for treating active psoriatic arthritis	No	
TA370	Bortezomib for previously untreated mantle cell lymphoma	No	
TA369	Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears	No	
TA374	Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy	No	
TA371	Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane	No	
TA368	Apremilast for treating moderate to severe plaque psoriasis	No	
TA364	Daclatasvir for treating chronic hepatitis C	No	
TA363	Ledipasvir–sofosbuvir for treating chronic hepatitis C	No	
TA365	Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C	No	
TA366	Pembrolizumab for advanced melanoma not previously treated with ipilimumab	No	
TA367	Vortioxetine for treating major depressive episodes	No	
TA539	Idelalisib for treating chronic lymphocytic leukaemia	No	

TA360	Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer	No	
TA362	Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal)	No	
TA357	Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab	No	
TA361	Simeprevir in combination with sofosbuvir for treating genotype 1 or 4 chronic hepatitis C (terminated appraisal)	No	
TA358	Tolvaptan for treating autosomal dominant polycystic kidney disease	No	
TA356	Ruxolitinib for treating polycythaemia vera (terminated appraisal)	No	
TA355	Atrial fibrillation (non-valvular) - edoxaban tosylate [ID624]	Yes	Yes
TA354	Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - edoxaban tosylate [ID662]	No	
TA353	Bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal)	No	
TA352	Crohn's disease (moderate to severe) - vedolizumab [ID690]	No	
TA345	Constipation (opioid-induced) - naloxegol [ID674]	Yes	Yes

TA349	Macular oedema (diabetic) - dexamethasone intravitreal implant [ID653]	No	
TA350	Psoriasis (plaque, moderate to severe) – secukinumab [ID718]	Yes	Yes
TA348	Organ rejection (liver transplantation, prevention) - everolimus [ID559]	No	
TA346	Macular oedema (diabetic) - aflibercept [ID717]	No	
TA347	Lung cancer (non-small cell) - nintedanib [ID438]	No	
TA344	Leukaemia (chronic lymphocytic, previously untreated) - ofatumumab	No	
TA343	Leukaemia (chronic lymphocytic) - obinutuzumab (with chlorambucil, 1st line)	No	
TA341	Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) – apixaban	Yes	Yes
TA313	Psoriatic arthritis (active) - ustekinumab (Rapid Rev	No	
TA349	Urticaria (chronic spontaneous, previously treated) - omalizumab Jun 15	No	
TA342	Ulcerative colitis (moderate to severely active) - vedolizumab Jun 15	No	
TA338	Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib (Mar15)	No	

TA337	Rifaximin for preventing episodes of overt hepatic encephalopathy (Mar15)	No	
TA336	Empagliflozin in combination therapy for treating type 2 diabetes (Mar15)	Yes	Yes
TA335	Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (Mar15)	Yes	Yes
TA334	Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) (Feb15)	No	
TA333	Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (Feb15)	No	
TA332	Sipuleucel-T for treating asymptomatic or minimally symptomatic metastatic hormone- relapsed prostate cancer (Feb15)	No	
TA331	Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C (Feb15)	No	
TA330	Sofosbuvir for treating chronic hepatitis C (Feb15)	No	
TA329	Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (Feb15)	No	
HST1	Eculizumab for treating atypical haemolytic uraemic syndrome (Jan15)	No	

TA328	Idelalisib for treating follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal) (Dec14)	No	
TA327	Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (Dec14)	No	
TA326	Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (Nov14)	No	
TA325	Nalmefene for reducing alcohol consumption in people with alcohol dependence (Nov14)	Yes	Yes
TA324	Dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block (Nov14)	No	
TA323	Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (Nov14)	Yes	Yes
TA321	Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (Oct14)	No	
TA322	Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (Sep14)	No	

TA320	Dimethyl fumarate for treating relapsing-remitting multiple sclerosis (Aug14)	No	
TA319	Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (Jul14)	No	
TA318	Lubiprostone for treating chronic idiopathic constipation (Jul14)	Yes	Yes
TA317	Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes Jul14)	Yes	Yes
TA316	Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen (Jul14)	No	
TA315	Canagliflozin in combination therapy for treating type 2 diabetes (TA315) (Jun14)	Yes	Yes
TA314	Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure (review of TA95 and TA120) (Jun14)	Yes	Yes
TA313	Psoriatic arthritis (active) - ustekinumab May 14)	No	
TA312	Multiple sclerosis (relapsing-remitting) - alemtuzumab (May14)	No	
TA311	Multiple myeloma - bortezomib (induction therapy) (Apr14)	No	



Locala Health & Wellbeing
Report of Compliance with NICE Technology Appraisals

TA310	Lung cancer (non small cell, EGFR mutation positive) - afatinib (Apr14)	No	
TA309	Lung cancer (non small cell, non squamous) - pemetrexed (Apr14)	No	No
	NICE TAs 2013-14		
	TA Subject	Is the recommendation in the TA applicable to organization?	Does Locala comply with the NICE Technology Appraisal?
TA308	Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids)	No	
TA307	Colorectal cancer (metastatic) - aflibercept	No	
TA306	Lymphoma (non Hodgkin's, relapsed, refractory) - pixantrone monotherapy (Feb'14)	No	
TA305	Macular oedema (central retinal vein occlusion) - aflibercept solution for injection (Feb'14)	No	
TA304	Arthritis of the hip (end stage) - hip replacement (total) and resurfacing arthroplasty (Rev TA2, TA44) (Feb'14)	No	
TA303	Multiple sclerosis (relapsing) - teriflunomide (Jan'14)	No	
TA302	Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) (Nov'13)	No	

TA301	Diabetic macular oedema - fluocinolone acetonide intravitreal implant (rapid review of TA271) (Nov'13)	Yes	Yes
TA300	Hepatitis C (children and young people) - peginterferon alfa and ribavirin (Nov'13)	No	
TA299	Bosutinib for previously treated chronic myeloid leukaemia (Nov'13)	No	
TA298	Choroidal neovascularisation (pathological myopia) - ranibizumab (Nov'13)	No	
TA297	Vitreomacular traction - ocriplasmin (October '13)	No	
TA296	Lung cancer (non-small-cell, anaplastic lymphoma kinase fusion gene, previously treated) - crizotinib (September '13)	No	
TA295	Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor) (August '13)	No	
TA294	Macular degeneration (wet age-related) aflibercept (July '13)	No	
TA293	Thrombocytopenic purpura - eltrombopag (July '13)	No	
TA292	Bipolar disorder (children) - aripiprazole (July '13)	Yes	Yes
TA291	Gout (tophaceous, severe debilitating, chronic) - pegloticase (June '13)	No	

TA290	Overactive bladder - mirabegron (June '13)	Yes	Yes
TA289	Myelofibrosis (splenomegaly, symptoms) - ruxolitinib (June'13)	No	
TA288	Type 2 diabetes - Dapagliflozin combination therapy (June '13)	Yes	Yes
TA287	Pulmonary embolism and recurrent venous thromboembolism - rivaroxaban (June '13)	Yes	Yes
TA286	Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) (May'13)	No	
TA285	Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum- sensitive advanced ovarian cancer (May'13)	No	
TA284	Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (May'13)	No	
TA283	Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion (May'13)	No	
TA282	Pirfenidone for treating idiopathic pulmonary fibrosis (Apr'13)	No	
TA281	Gout - canakinumab (terminated appraisal) (Apr'13)	No	

TA280	Abatacept for treating rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs (rapid review of technology appraisal guidance 234) (Apr'13)	No	
TA279	Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for the treatment of osteoporotic vertebral fractures (Apr'13)	No	
TA278	Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 and over and adults (review of TA133 and TA201) (Apr'13)	No	
	NICE TAs 2012-13		
	TA Subject	Is the recommendation in the TA applicable to organization?	Does Locala comply with the NICE Technology Appraisal?
TA277	Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness	No	
TA276	Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin	No	
TA275	Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban	Yes	Yes
TA274	Macular oedema (diabetic) - ranibizumab	No	
TA273	Hyperplasia (benign prostatic) - tadalafil (terminated appraisal)	No	
TA272	Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine	No	
TA271	Diabetic macular oedema - fluocinolone acetonide intravitreal implant	No	

TA270	Leukaemia (acute myeloid) - decitabine (terminated appraisal)	No	
TA269	Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib	No	
TA268	Melanoma (stage III or IV) - ipilimumab	No	
TA267	Chronic heart failure - ivabradine	No	
TA266	Cystic fibrosis - mannitol dry powder for inhalation	No	

TA265	Bone metastases from solid tumours - denosumab	Yes	Yes
TA264	Stroke (acute, ischaemic) - alteplase	No	
TA263	Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer	No	
TA262	Ulcerative colitis (moderate to severe, second line) - adalimumab (terminated appraisal)	No	
TA261	Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban	Yes	Yes
TA260	Migraine (chronic) - botulinum toxin type A	No	
TA259	Prostate cancer (metastatic, castration resistant) - abiraterone (following cytotoxic therapy)	Yes	Yes
TA258	Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line)	No	
TA257	Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor)	No	
TA256	Atrial fibrillation (stroke prevention) - rivaroxaban	Yes	Yes
TA255	Prostate cancer - cabazitaxel	Yes	Yes

TA254	Multiple sclerosis (relapsing- remitting) - fingolimod	No	
TA253	Hepatitis C (genotype 1) - boceprevir	No	
TA252	Hepatitis C (genotype 1) - telaprevir	No	
TA251	Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib	No	
TA250	Breast cancer (advanced) - eribulin	No	
	NICE TAs 2011-12		
	TA Subject	Is the recommendation in the TA applicable to organization?	Does Locala comply with the NICE Technology Appraisal?
TA249	Atrial fibrillation - dabigatran etexilate	Yes	Yes
TA248	Diabetes (type 2) - exenatide (prolonged release)	Yes	Yes
TA247	Rheumatoid arthritis - tocilizumab (rapid review TA198)	No	
TA246	Venom anaphylaxis - immunotherapy pharmlagen	Yes	Yes
TA245	Venous thromboembolism - apixaban (hip and knee surgery)	Yes	Yes
TA244	Chronic obstructive pulmonary disease - roflumilast	No	

TA243	Follicular lymphoma - rituximab (review)	No	
TA242	Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)	No	
TA241	Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant)	No	
TA240	Colorectal cancer (metastatic) - panitumumab (terminated appraisal)	No	
TA239	Breast cancer (metastatic) - fulvestrant	No	
TA238	Arthritis (juvenile idiopathic, systemic) - tocilizumab	No	
TA237	Macular oedema (diabetic) - ranibizumab	No	
TA236	Acute coronary syndromes - ticagrelor	Yes	
TA235	Osteosarcoma - mifamurtide	No	